The amendment is designed to test the safety and efficacy of lower and higher doses of Intravitreal (IVT) LFG316 using single and 18 successive monthly injections in patients with geographic atrophy (GA). The study will also provide information on the safety, tolerability, serum concentrations and pharmacodynamics of single and multiple IVT doses of LFG316.